Improving Vaccine Coverage in the United States

The Inflation Reduction Act has helped close gaps in insurance coverage for vaccines, including newly approved ones. With the introduction of mRNA vaccines, vaccine technology has made significant strides. Different federal policies dictate coverage across different markets and populations, creating a fragmented insurance and policy landscape. The Affordable Care Act and the Inflation Reduction Act have played key roles in ensuring coverage without cost-sharing for many vaccines in various markets. ACIP recommendations are a major driver of provider behavior and payer coverage. The FDA approved six vaccines in 2023, including the first two vaccines to prevent respiratory syncytial virus for older adults and infants. GSK’s Arexvy and Pfizer’s Abrysvo were both approved for RSV prevention in 2023.